Recent advances in our understanding of Parkinson's disease

Drug Discovery Today: Disease Mechanisms

Volumn 2, Issue 4, 2005, Pages 427-433

  Kim, Seong Who ^a,b   Ko, Han Seok ^a   Dawson, Valina L ^a   Dawson, Ted M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMPA RECEPTOR ANTAGONIST; ASCORBIC ACID; CASPASE INHIBITOR; CATECHOL METHYLTRANSFERASE INHIBITOR; CHELATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; GENE PRODUCT; GPI 1485; LEVODOPA; METAL CHELATOR; MINOCYCLINE; MONOAMINE OXIDASE B INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRIC OXIDE SYNTHASE INHIBITOR; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROTEASOME; PROTEIN INHIBITOR; PROTEIN P53 INHIBITOR; REACTIVE OXYGEN METABOLITE; SCAVENGER; SEROTONIN 1A AGONIST; UBIDECARENONE; UBIQUITIN; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHRONIC DISEASE; DEGENERATIVE DISEASE; HUMAN; MITOCHONDRION; NERVE CELL NECROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN FOLDING; REVIEW;

EID: 33645063196     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2005.11.015     Document Type: Review

References (40)

1. T.M. Dawson V.L. Dawson Molecular pathways of neurodegeneration in Parkinson's disease Science 302 2003 819-822
2. D.J. Moore et. al. Molecular pathophysiology of Parkinson's disease Annu. Rev. Neurosci. 28 2005 57-87
3. M.G. Spillantini et. al. Alpha-synuclein in Lewy bodies Nature 388 1997 839-840
4. T. Taira et. al. DJ-1 has a role in antioxidative stress to prevent cell death EMBO Rep. 5 2004 213-218
5. A. Beilina et. al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability Proc. Natl. Acad. Sci. U S A 102 2005 5703-5708
6. A.B. Singleton Altered alpha-synuclein homeostasis causing Parkinson's disease: The potential roles of dardarin Trends Neurosci. 28 2005 416-421
7. C.W. Olanow W.G. Tatton Etiology and pathogenesis of Parkinson's disease Annu. Rev. Neurosci. 22 1999 123-144
8. J. Lotharius P. Brundin Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein Nat. Rev. Neurosci. 3 2002 932-942
9. T.G. Hastings et. al. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections Proc. Natl. Acad. Sci. U S A 93 1996 1956-1961
10. D.C. Jones et. al. Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells J. Neurochem. 74 2000 2296-2304
11. D.G. Graham Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones Mol. Pharmacol. 14 1978 633-643
12. A. Hald J. Lotharius Oxidative stress and inflammation in Parkinson's disease: Is there a causal link? Exp. Neurol. 193 2005 279-290
13. M.F. Beal Mitochondria, oxidative damage, and inflammation in Parkinson's disease Ann. N. Y. Acad. Sci. 991 2003 120-131
14. N.W. Kowall et. al. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons Neuroreport 11 2000 211-213
15. A.I. Brooks et. al. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss Brain Res. 823 1999 1-10
16. A.B. Manning-Bog et. al. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: Paraquat and alpha-synuclein J. Biol. Chem. 277 2002 1641-1644
17. R.H. Swerdlow et. al. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family Ann. Neurol. 44 1998 873-881
18. J.M. van der Walt et. al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease Am. J. Hum. Genet. 72 2003 804-811
19. M.F. Beal Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment J. Bioenerg. Biomembr. 36 2004 381-386
20. C.A. Ross C.M. Pickart The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases Trends Cell Biol. 14 2004 703-711
21. K.S. McNaught C.W. Olanow Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson's disease Ann. Neurol. 53 Suppl. 3 2003 S73-S84
22. N. Hattori Y. Mizuno Pathogenetic mechanisms of parkin in Parkinson's disease Lancet 364 2004 722-724
23. H.S. Ko et. al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death J. Neurosci. 25 2005 7968-7978
24. K.L. Lim et. al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: Implications for Lewy body formation J. Neurosci. 25 2005 2002-2009
25. D. Lundvig et. al. Pathogenic effects of alpha-synuclein aggregation Brain Res. Mol. Brain Res. 134 2005 3-17
26. M. Hashimoto et. al. Beta-synuclein inhibits alpha-synuclein aggregation: A possible role as an anti-parkinsonian factor Neuron 32 2001 213-223
27. M.R. Cookson The biochemistry of Parkinson's disease Annu. Rev. Biochem. 74 2005 29-52
28. F. Fornai et. al. Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and alpha-synuclein Proc. Natl. Acad. Sci. U S A 102 2005 3413-3418
29. A.M. Cuervo et. al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy Science 305 2004 1292-1295
30. B.I. Giasson et. al. Initiation and synergistic fibrillization of tau and alpha-synuclein Science 300 2003 636-640
31. M. Meulener et. al. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease Curr. Biol. 15 2005 1572-1577
32. M.S. Goldberg et. al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial parkinsonism-linked gene DJ-1 Neuron 45 2005 489-496
33. D. Nagakubo et. al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras Biochem. Biophys. Res. Commun. 231 1997 509-513
34. R.H. Kim et. al. DJ-1, a novel regulator of the tumor suppressor PTEN Cancer Cell 7 2005 263-273
35. E.M. Valente et. al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1 Science 304 2004 1158-1160
36. A. Petit et. al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations J. Biol. Chem. 280 2005 34025-34032
37. A.B. West et. al. Parkinson's disease associated mutations in leucine-rich repeat kinase 2 augment kinase activity Proc. Natl. Acad. Sci. U S A 102 2005 16842-16847
38. T.M. Dawson V.L. Dawson Neuroprotective and neurorestorative strategies for Parkinson's disease Nat. Neurosci. 5 Suppl. 2002 1058-1061
39. R.A. Hauser K.E. Lyons Future therapies for Parkinson's disease Neurol. Clin. 22 3 Suppl. 2004 S149-S166
40. T.D. Halbig et. al. Neuroprotective agents in Parkinson's disease: clinical evidence and caveats Neurol. Clin. 22 3 Suppl. 2004 S1-S17